Ann: Phase 1 CF33-hNIS Study Update - Positive Early Signals, page-82

First 82 Last

Share
Profile

Follow
AlCp

27,899 Posts.

1797

17/01/24

14:25

Post #: 71924179
Share

Originally posted by nayr ↑

Does anyone else have difficulty when trying to interpret the results of clinical trials as reported by IMU?

The data looks good from what I can interpret, but if they could present it with more clarity and structure then I’m sure it would become even more enlightening for shareholders and others.

We know that in relation to the MAST trial: CF33-hNIS is administered alone, or in combination with pembrolizumab and either dosed intravenously (IV) or intratumourally (IT). But do we really know for example how many patients treated with pembro intratumourally have had a partial response?

We know that: As of 12 January 2024, 38 patients have been dosed with VAXINIA during the continuing dose escalation phase, comprised of 19 patients dosed intratumourally and 19 patients dosed intravenously as either monotherapy or in combination with pembrolizumab. And that: 31 patients were evaluable for efficacy (received at least their first scan at day 42).

But it does get a bit messy.

In the IT cohorts (14 patients), 7 of 15 (47%) [should this be 7 of 14 (50%)?] injected lesions had a reduction in tumour burden [so Partial Response?], 3 lesions were completely eradicated [so Complete Response?].

The report then goes on to state that: 3 patients (21%) had an objective response [Objective response defined as patients with a complete or partial response; 1 complete response by iRECIST in a patient with cholangiocarcinoma (a type of biliary tract cancer); and 2 partial responses in patients with melanoma (skin cancer) by RECIST.

So we have this: 7 lesions with a reduction in tumour burden; 3 lesions completely eradicated; 3 patients with an OR; 1 CR; and 2 PR. The numbers don’t compute or must include some double counting.

It is a bit clearer for IV cohorts: 17 patients, 53% of patients [Must be 9 patients] achieved stable disease as their best response.

Then later: 7 patients with gastrointestinal cancers who received CF33-hNIS alone including 3 colorectal, 2 biliary tract, 1 pancreatic and 1 liver cancer showed positive treatment effects, with a disease control rate (all CR, PR and SD) of 86%. How is the 86% calculated? [7 patients out of 8 = 87.5%] We know from the above information that there were 2 non-gastro PR (melanomas) so again the numbers don’t compute.

It would be nice to know exactly how many CR + PR+ SD we have as a result of this study and how they are categorized by IV or IT and mono or pembro and by type of cancer.

I’m sure that some of our brightest contributors can help clarify.

Expand

The market did respond to 12c and then got bonked again back to 10.5c.

IMU Price at posting: 10.5¢ Sentiment: None Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

ASX Market Open: Trump-led market run falters in new week | November 18, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

First 82 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.1¢		Change -0.003(6.82%)		Mkt cap ! $304.9M

Open	High	Low	Value	Volume
4.3¢	4.4¢	4.1¢	$1.607M	38.52M

Buyers (Bids)

No.	Vol.	Price($)
23	4542680	4.1¢

Sellers (Offers)

Price($)	Vol.	No.
4.3¢	1675759	9

View Market Depth

No.	Vol.	Price($)
15	2598776	0.041
76	6281075	0.040
31	5664241	0.039
15	2789416	0.038
10	1400513	0.037

Price($)	Vol.	No.
0.043	1652096	8
0.044	1145733	8
0.045	1715026	12
0.046	1642231	7
0.047	1652765	8

Last trade - 16.10pm 15/11/2024 (20 minute delay)

IMU (ASX) Chart

Ann: Phase 1 CF33-hNIS Study Update - Positive Early Signals, page-82

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

ASX Market Open: Trump-led market run falters in new week | November 18, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Phase 1 CF33-hNIS Study Update - Positive Early Signals, page-82

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

ASX Market Open: Trump-led market run falters in new week | November 18, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News